| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced financial results for the third quarter of 2026. All financial information in this press release is reported in U.S. dollars, unless otherwise indica... |
| 13 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
Introductory. AbCellera Biologics Inc., a corporation incorporated under the Business Corporations Act (British Columbia) (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i... |
| 10 Aug 2026 |
8-K: Regulation FD Disclosure
These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking... |
| 07 Aug 2026 |
8-K: Other Events
150 W 4th Ave Vancouver, BC V5Y 1G6 T 1. 604.559.9005 abcellera.com NEWS RELEASE AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to- Severe VMS Due to Menopause on Monday, August 10,... |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced financial results for the second quarter of 2026. All financial information in this press release is reported in U.S. dollars, unless otherwise indic... |
| 29 Jul 2026 |
8-K: Other Events
150 W 4th Ave Vancouver, BC V5Y 1G6 T 1. 604.559.9005 abcellera.com NEWS RELEASE AbCellera Announces Collaboration with Vertex to Discover Multispeci�c T-Cell Engagers for Autoimmune Diseases and Other Conditions 2026-07-29 VANCOUVER, Br... |
| 06 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On June 30, 2026, the Board of Directors (the "Board") of AbCellera Biologics Inc. (the "Company") appointed Lynn Seely, M.D as a new Class III director. Dr. Seely will serve until the Company’s 2029 annual meeting of shareholders and un... |
| 17 Jun 2026 |
8-K: Other Events
150 W 4th Ave Vancouver, BC V5Y 1G6 T 1. 604.559.9005 abcellera.com NEWS RELEASE Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispeci�c Antibodies 2026-06-17 The collaboration i... |
| 12 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
AbCellera Biologics Inc. (the “Company”) held its Annual Meeting of Shareholders (the “Annual Meeting”) on June 11, 2026. As of April 15, 2026, the record date for the Annual Meeting, there were 305,264,947 common shares of the Company o... |
| 05 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
150 W 4th Ave Vancouver, BC V5Y 1G6 T 1. 604.559.9005 abcellera.com NEWS RELEASE AbCellera Appoints Dr. Victor Sandor to its Board of Directors 2026-06-05 VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today anno... |
| 11 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635 |
| 24 Feb 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced financial results for the full year 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. |
| 14 Jan 2026 |
8-K: Regulation FD Disclosure
CO PY RI GH T © A BC EL LE RA January 14, 2025 AbCellera Corporate Overview |
| 18 Dec 2025 |
8-K: Regulation FD Disclosure
AbCellera and Bruker Reach Global Settlement of Patent Litigation VANCOUVER, British Columbia-- AbCellera (Nasdaq: ABCL) today announced that it has entered into a settlement and patent license agreement with Bruker Corporation, resolvin... |
| 28 Nov 2025 |
8-K: Changes in Registrant's Certifying Accountant
November 28, 2025 Securities and Exchange Commission Washington, D.C. 20549 Ladies and Gentlemen: We are currently principal accountants for AbCellera Biologics Inc. (the Company) and, under the date of February 27, 2025, we reported on ... |
| 12 Nov 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
150 W 4th Ave Vancouver, BC V5Y 1G6 T 1. 604.559.9005 abcellera.com NEWS RELEASE AbCellera Appoints Dr. Stephen Quake to its Board of Directors 2025-11-10 VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today anno... |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced financial results for the third quarter of 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indica... |
| 10 Sep 2025 |
8-K: Other Events
150 W 4th Ave Vancouver, BC V5Y 1G6 T 1. 604.559.9005 abcellera.com NEWS RELEASE AbCellera Appoints Dr. Sarah Noonberg as Chief Medical O�cer 2025-09-10 VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announ... |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms |
| 13 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
AbCellera Biologics Inc. (the “Company”) held its Annual Meeting of Shareholders (the “Annual Meeting”) on June 12, 2025. As of April 15, 2025, the record date for the Annual Meeting, there were 298,423,569 common shares of the Company o... |
Loading...